NasdaqGM:RMTI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.


Similar Companies

Share Price & News

How has Rockwell Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RMTI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: RMTI's weekly volatility has decreased from 14% to 8% over the past year.


Market Performance


7 Day Return

18.3%

RMTI

0.5%

US Medical Equipment

2.3%

US Market


1 Year Return

-44.7%

RMTI

20.7%

US Medical Equipment

23.8%

US Market

Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned 20.7% over the past year.

Return vs Market: RMTI underperformed the US Market which returned 23.8% over the past year.


Shareholder returns

RMTIIndustryMarket
7 Day18.3%0.5%2.3%
30 Day40.6%3.5%4.8%
90 Day47.9%7.2%14.5%
1 Year-44.7%-44.7%21.7%20.7%26.6%23.8%
3 Year-74.7%-74.7%64.7%60.6%45.0%35.4%
5 Year-77.3%-77.3%166.9%147.1%126.2%101.0%

Long-Term Price Volatility Vs. Market

How volatile is Rockwell Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Rockwell Medical undervalued compared to its fair value and its price relative to the market?

3.16x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate RMTI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate RMTI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: RMTI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: RMTI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RMTI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RMTI is good value based on its PB Ratio (3.2x) compared to the US Medical Equipment industry average (5.7x).


Next Steps

Future Growth

How is Rockwell Medical forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

89.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RMTI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: RMTI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: RMTI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: RMTI's revenue (23.2% per year) is forecast to grow faster than the US market (10.6% per year).

High Growth Revenue: RMTI's revenue (23.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RMTI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Rockwell Medical performed over the past 5 years?

-16.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RMTI is currently unprofitable.

Growing Profit Margin: RMTI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RMTI is unprofitable, and losses have increased over the past 5 years at a rate of 16.4% per year.

Accelerating Growth: Unable to compare RMTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RMTI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).


Return on Equity

High ROE: RMTI has a negative Return on Equity (-70.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is Rockwell Medical's financial position?


Financial Position Analysis

Short Term Liabilities: RMTI's short term assets ($77.9M) exceed its short term liabilities ($12.7M).

Long Term Liabilities: RMTI's short term assets ($77.9M) exceed its long term liabilities ($30.5M).


Debt to Equity History and Analysis

Debt Level: RMTI's debt to equity ratio (49.6%) is considered high.

Reducing Debt: Insufficient data to determine if RMTI's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RMTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: RMTI has sufficient cash runway for 2.2 years if free cash flow continues to reduce at historical rates of 26.7% each year.


Next Steps

Dividend

What is Rockwell Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RMTI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RMTI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RMTI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RMTI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RMTI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Russell Ellison (72 yo)

0.75

Tenure

Dr. Russell H. Ellison, M.D., M.Sc., serves as President and Chief Executive Officer at Rockwell Medical, Inc. since April 17, 2020 and serves as its Director since January 09, 2020. He served as a consult...


Leadership Team

NamePositionTenureCompensationOwnership
Ajay Gupta
Chief Scientific Officer & Member of Scientific Advisory Board15.17yrsUS$736.73k0.60%
$ 800.0k
Russell Ellison
President0.75yrno data0.0021%
$ 2.8k
Russell Skibsted
Executive VP0.33yrno datano data
Michael DeYoung
Vice President of Operations2.08yrsno datano data
Paul McGarry
VP, Corporate Controller & Principal Accounting Officer1.58yrsno datano data
Michael Costello
General Counselno datano datano data
James McCarthy
Senior Vice President of Business & Corporate Development2.33yrsno datano data
Anne Boardman
Vice President of Sales and Strategic Accounts2.25yrsno datano data
Tim Chole
Vice President of Marketing1yrno datano data
Raymond Pratt
Chief Development Officer8.75yrsUS$965.87k0.35%
$ 463.9k
David Kull
Secretary1.58yrsno data0.0035%
$ 4.6k
Marc Hoffman
Chief Medical Officer1.17yrsno datano data

1.6yrs

Average Tenure

61yo

Average Age

Experienced Management: RMTI's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Ajay Gupta
Chief Scientific Officer & Member of Scientific Advisory Board15.17yrsUS$736.73k0.60%
$ 800.0k
Russell Ellison
President0.75yrno data0.0021%
$ 2.8k
John Cooper
Independent Director3.33yrsUS$288.43k0.021%
$ 28.2k
John McLaughlin
Independent Chairman1.25yrsUS$119.73kno data
Anatole Besarab
Member of Medical Advisory Board15.17yrsno datano data
Rajiv Agarwal
Member of Scientific Advisory Board15.17yrsno datano data
Iain MacDougall
Member of Scientific Advisory Board10.42yrsno datano data
Alvin Crumbliss
Member of Scientific Advisory Board9.75yrsno datano data
Francesco Locatelli
Member of Scientific Advisory Board8yrsno datano data
Mark Ravich
Independent Director3.58yrsUS$197.93k0.45%
$ 593.1k
George Aronoff
Member of Scientific Advisory Board2yrsno datano data
Gary Brittenham
Member of Scientific Advisory Board5yrsno datano data

6.5yrs

Average Tenure

67yo

Average Age

Experienced Board: RMTI's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: RMTI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.3%.


Top Shareholders

Company Information

Rockwell Medical, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Rockwell Medical, Inc.
  • Ticker: RMTI
  • Exchange: NasdaqGM
  • Founded: 1994
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$132.874m
  • Shares outstanding: 93.57m
  • Website: https://www.rockwellmed.com

Number of Employees


Location

  • Rockwell Medical, Inc.
  • 411 Hackensack Avenue
  • Suite 501
  • Hackensack
  • New Jersey
  • 7601
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RMTINasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1998
RWMDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1998

Biography

Rockwell Medical, Inc. operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialy...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/24 00:21
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.